Business Association Chemistry Pharma Life Sciences
Introduction to the cost containment packages

Dossiers - Reforms in the healthcare sector

Introduction to the cost containment packages

The chemical, pharmaceutical and life sciences industries have an interest in maintaining a sound and stable healthcare system, which is why scienceindustries is actively involved in the process of implementing the cost containment programme.

13.11.2026

The chemical, pharmaceutical and life sciences industries have an interest in a high-quality, affordable healthcare system that remains stable over the long term. scienceindustries therefore closely follows health policy efforts to contain costs and advocates for continued or faster patient access to both established and innovative medicines on appropriate terms.

Round Table on Cost Containment

Federal Councillor Elisabeth Baume-Schneider launched the Round Table on Cost Containment in November 2024. It provides a forum for dialogue among key healthcare stakeholders and for jointly developing measures to contain healthcare costs. The aim is to eliminate perverse incentives and inefficiencies in the healthcare system and strengthen the long-term financial sustainability of healthcare provision.

The pharmaceutical industry is represented at the Round Table by the President of scienceindustries. In addition, the Chair of scienceindustries’ Pharmaceutical Policy Committee (PPG) sits on the expert group that provides technical preparation and support for the Round Table’s work. The pharmaceutical industry’s concerns and positions are coordinated within an industry sounding board, with due regard for confidentiality, and brought to the expert group.

As part of this process, scienceindustries advocates for cost-containment measures that focus on eliminating perverse incentives and inefficiencies. These measures should contribute to an efficient and financially sustainable healthcare system without restricting access to innovative and established medicines or placing a disproportionate burden on the pharmaceutical industry.

Cost containment package 1

In August 2019, the Federal Council adopted a first cost-containment programme for submission to Parliament. It aims to hold all healthcare stakeholders accountable and ensure that costs increase only to the extent that is medically justified. Deliberations on this first package of measures were divided into two sub-packages (1a and 1b). While our industry primarily followed the debate on the experimentation clause in package 1a, package 1b comprises three proposals: measures for cost management by tariff partners, a reference pricing system for medicines and a right for insurers to appeal against cantonal hospital planning decisions.

Both chambers of Parliament concluded their deliberations on sub-package 1a during the 2021 summer session. The industry noted with relief that, unlike the Federal Council, neither chamber wished to provide for compulsory participation under the experimentation clause. When the new experimentation clause is implemented and applied, it will be important to ensure that it does not undermine the principle of territoriality.

Following lengthy deliberations, the two chambers of the Swiss Parliament adopted cost containment package 1b (CCP 1b) during the 2022 autumn session. The package now provides for cost monitoring in the healthcare system. However, the Confederation and the cantons are not to be given powers to intervene if the tariff partners cannot reach an agreement. Encouragingly, Parliament dropped the reference pricing system for generics in the first round of deliberations, but mandatory simplifications are now being introduced for the authorisation of parallel-imported medicines.

scienceindustries notes with relief that the National Council’s original decision to bypass Swissmedic for medicine imports has been dropped, as this would have created serious uncertainty for Switzerland’s supply of medicines. The two chambers have also agreed to grant health insurance associations a right of appeal against cantonal hospital planning decisions. The rules governing pharmacists’ right to substitute medicines have likewise been amended.

Cost containment package 2

In August 2020, the consultation on a second package of measures to contain healthcare costs (CCP 2) was launched. scienceindustries submitted its consultation response on 19 November 2020. On 7 September 2022, the Federal Council adopted the dispatch on CCP 2 (22.062) for submission to Parliament. The proposals include networks to promote coordinated care and improve the quality of healthcare provision. The Federal Council also aims to ensure rapid access to innovative medicines at the lowest possible cost, while revising the rules for reviewing the criteria for reimbursement under basic health insurance: efficacy, appropriateness and cost-effectiveness (the WZW criteria).

The second cost containment package was adopted by the two chambers of the Swiss Parliament on 21 March 2025. The measures adopted are now being specified step by step at ordinance level. For the pharmaceutical industry, the implementation of budget impact models (volume discounts), the strengthening of pricing models, provisional reimbursement of medicines from the date of authorisation (“day 0”), and a differentiated review of the WZW criteria are particularly relevant.

scienceindustries contributed to the consultation on implementing the measures relating to medicines in spring 2026, highlighting in particular the importance of reliable framework conditions, security of supply and rapid access to innovative medicines. In summer 2026, the health committees of the National Council and the Council of States recommended deferring the implementation of most measures relating to medicines until the findings of the “Life Sciences Hub” working group are available. However, the differentiated WZW review for generics and other low-cost medicines should proceed. scienceindustries welcomes this approach and advocates for further work to take account of the competitiveness of Switzerland as a pharmaceutical hub and the supply of innovative and established medicines.

 


Close

Newsletter subscription

scienceindustries News
Standpoints
Point